

Nicholas Pavlidis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3446885/publications.pdf>

Version: 2024-02-01

183
papers

8,891
citations

36303

51
h-index

49909

87
g-index

190
all docs

190
docs citations

190
times ranked

9451
citing authors

#	ARTICLE	IF	CITATIONS
1	ESO-ESSO-ESTRO Multidisciplinary Course in Oncology for Medical Students: 4 Years of Experience (2016â€“2019). <i>Journal of Cancer Education</i> , 2022, 37, 1239-1244.	1.3	7
2	ESO's career development program (2002-2021): Presentation and evaluation. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103576.	4.4	0
3	Systematic review of the CUP trials characteristics and perspectives for next-generation studies. <i>Cancer Treatment Reviews</i> , 2022, 107, 102407.	7.7	13
4	Changing the landscape of European School of Oncologyâ€™European Society for Medical Oncology masterclasses in clinical oncology during the COVID-19 pandemic. <i>Future Oncology</i> , 2022, 18, 2857-2864.	2.4	1
5	Sarcoma of unknown primary: myth or reality?. <i>Journal of the Egyptian National Cancer Institute</i> , 2022, 34, .	1.5	1
6	Chromosomal instability in cancers of unknown primary. <i>European Journal of Cancer</i> , 2022, 172, 323-325.	2.8	7
7	ESO-ESMO Masterclass in Clinical Oncology: Analysis and Evaluation of the Learning Self-Assessment Test. <i>Journal of Cancer Education</i> , 2021, 36, 556-560.	1.3	5
8	The management of patients with cancer of unknown primary in middle-income countries: an ESO-AROME survey. <i>Future Oncology</i> , 2021, 17, 151-157.	2.4	2
9	Melanoma of unknown primary: New perspectives for an old story. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 158, 103208.	4.4	37
10	Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities. <i>Annals of Translational Medicine</i> , 2021, 9, 423-423.	1.7	6
11	Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 329-333.	3.4	39
12	Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13583.	3.4	15
13	The Contribution of the European School Of Oncology Education to the Central Asian and Caucasian Regions. <i>Journal of Cancer Education</i> , 2021, , 1.	1.3	1
14	Live European School of Oncology e-Sessions (e-ESO). <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103301.	4.4	1
15	Educational contribution of the College of the European School of Oncology to the Latin American Oncologists. <i>Future Oncology</i> , 2021, 17, 2981-2987.	2.4	1
16	Eight-Year Experience of the Certificate of Competence and Advanced Studies Program Organized by the European School of Oncology. <i>Journal of Cancer Education</i> , 2021, , 1.	1.3	1
17	The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry. <i>Cancer Epidemiology</i> , 2021, 75, 102045.	1.9	35
18	Cancer of unknown primary: Incidence rates, risk factors and survival among adolescents and young adults. <i>International Journal of Cancer</i> , 2020, 146, 1490-1498.	5.1	19

#	ARTICLE	IF	CITATIONS
19	Changing the education paradigm in oncology: ESO masterclass, 17 years of continuous success. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 146, 102798.	4.4	9
20	Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. <i>Investigational New Drugs</i> , 2020, 38, 181-193.	2.6	70
21	Synovial Sarcoma: A Complex Disease with Multifaceted Signaling and Epigenetic Landscapes. <i>Current Oncology Reports</i> , 2020, 22, 124.	4.0	8
22	The impact of the European School of Oncology masterclass in clinical oncology on self-professional development. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102976.	4.4	5
23	The diagnostic challenges of patients with carcinoma of unknown primary. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 775-783.	2.4	12
24	What can we learn from cancer of unknown primary in canine oncology?. <i>Journal of Advanced Research</i> , 2020, 24, 495-500.	9.5	3
25	Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond. <i>Drugs in R and D</i> , 2020, 20, 55-73.	2.2	84
26	The clinical training centers fellowships: a European School of Oncology career development program (2013-2019). <i>Future Oncology</i> , 2020, 16, 1969-1976.	2.4	5
27	Exploring the biological hallmarks of cancer of unknown primary: where do we stand today?. <i>British Journal of Cancer</i> , 2020, 122, 1124-1132.	6.4	41
28	New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 147, 102882.	4.4	42
29	The role of site-specific therapy for cancers of unknown of primary: A meta-analysis. <i>European Journal of Cancer</i> , 2020, 127, 118-122.	2.8	24
30	Progress in refining the clinical management of cancer of unknown primary in the molecular era. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 541-554.	27.6	62
31	Clinical Case Presentation and Discussion During ESO-ESMO Masterclass: a 10-Year Interactive Educational Experience. <i>Journal of Cancer Education</i> , 2020, 36, 1124-1128.	1.3	5
32	Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answered. <i>Annals of Translational Medicine</i> , 2020, 8, 1709-1709.	1.7	7
33	Ovarian cancer: state of the art and perspectives of clinical research. <i>Annals of Translational Medicine</i> , 2020, 8, 1702-1702.	1.7	2
34	Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?. <i>Annals of Translational Medicine</i> , 2020, 8, 1706-1706.	1.7	17
35	Wise Management of Ovarian Cancer: On the Cutting Edge. <i>Journal of Personalized Medicine</i> , 2020, 10, 41.	2.5	51
36	Advances in the management of brain metastases from cancer of unknown primary. <i>Future Oncology</i> , 2019, 15, 2759-2768.	2.4	4

#	ARTICLE	IF	CITATIONS
37	The interaction of immune checkpoint inhibitor plus chemotherapy in non-small-cell lung cancer: subadditivity, additivity or synergism?. <i>Immunotherapy</i> , 2019, 11, 913-920.	2.0	13
38	Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review. <i>Diagnostics</i> , 2019, 9, 87.	2.6	94
39	Comprehensive management of HPV-related squamous cell carcinoma of the head and neck of unknown primary. <i>Head and Neck</i> , 2019, 41, 3700-3711.	2.0	40
40	The currently declining incidence of cancer of unknown primary. <i>Cancer Epidemiology</i> , 2019, 61, 139-141.	1.9	71
41	Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Future Oncology</i> , 2019, 15, 909-923.	2.4	10
42	Familial cancer of unknown primary. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1328-1331.	2.2	11
43	PARP Inhibitors in Ovarian Cancer: The Route to "elthaca". <i>Diagnostics</i> , 2019, 9, 55.	2.6	52
44	A new entity of abdominal squamous cell carcinoma of unknown primary. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13111.	3.4	14
45	The Developing Story of Predictive Biomarkers in Colorectal Cancer. <i>Journal of Personalized Medicine</i> , 2019, 9, 12.	2.5	111
46	Paraneoplastic syndromes in cancers of unknown primary: An unknown field for oncologists. <i>Bulletin Du Cancer</i> , 2019, 106, 590-603.	1.6	9
47	A review on pregnancy complicated by ovarian epithelial and non-epithelial malignant tumors: Diagnostic and therapeutic perspectives. <i>Journal of Advanced Research</i> , 2018, 12, 1-9.	9.5	37
48	The current evidence for a biomarker-based approach in cancer of unknown primary. <i>Cancer Treatment Reviews</i> , 2018, 67, 21-28.	7.7	30
49	Extranodal diffuse large B-cell lymphomas: A retrospective case series and review of the literature. <i>Hematology Reports</i> , 2018, 10, 7070.	0.8	14
50	Liquid biopsy: a new diagnostic, predictive and prognostic window in cancers of unknown primary. <i>European Journal of Cancer</i> , 2018, 105, 28-32.	2.8	19
51	A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma origin. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 60-69.	4.4	20
52	Depression in cancer: The many biobehavioral pathways driving tumor progression. <i>Cancer Treatment Reviews</i> , 2017, 52, 58-70.	7.7	204
53	Testicular Signet-Ring Cell Metastasis from a Carcinoma of Unknown Primary Site: A Case Report and Literature Review. <i>Case Reports in Oncological Medicine</i> , 2016, 2016, 1-5.	0.3	1
54	The ESMO/ASCO Global Curriculum and the evolution of medical oncology training in Europe. <i>ESMO Open</i> , 2016, 1, e000004.	4.5	12

#	ARTICLE	IF	CITATIONS
55	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 2016, 1, e000097.	4.5	82
56	Lung cancer during pregnancy: A narrative review. Journal of Advanced Research, 2016, 7, 571-574.	9.5	35
57	Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review. Critical Reviews in Oncology/Hematology, 2016, 108, 164-174.	4.4	134
58	Age-Dependent Metastatic Spread and Survival: Cancer of Unknown Primary as a Model. Scientific Reports, 2016, 6, 23725.	3.3	14
59	Aromatase inhibitors induced autoimmune disorders in patients with breast cancer: A review. Journal of Advanced Research, 2016, 7, 719-726.	9.5	26
60	Bone and soft tissue sarcomas during pregnancy: A narrative review of the literature. Journal of Advanced Research, 2016, 7, 581-587.	9.5	17
61	A mini review on pregnant mothers with cancer: A paradoxical coexistence. Journal of Advanced Research, 2016, 7, 559-563.	9.5	13
62	Sense of Coherence and Defense Style Predict Sleep Difficulties in Early Non-metastatic Colorectal Cancer. Digestive Diseases and Sciences, 2016, 61, 273-282.	2.3	9
63	Cancer specific risk in multiple sclerosis patients. Critical Reviews in Oncology/Hematology, 2016, 98, 29-34.	4.4	21
64	Prognostic significance of <scp>WNT</scp> and hedgehog pathway activation markers in cancer of unknown primary. European Journal of Clinical Investigation, 2015, 45, 1145-1152.	3.4	4
65	Neuroendocrine Cell Carcinoma of Unknown Primary Arising in Long Standing History of Multiple Sclerosis. Case Reports in Oncological Medicine, 2015, 2015, 1-4.	0.3	1
66	Neuroendocrine Merkel cell nodal carcinoma of unknown primary site: Management and outcomes of a rare entity. Critical Reviews in Oncology/Hematology, 2015, 94, 116-121.	4.4	23
67	Gastrointestinal stromal tumors during pregnancy: a systematic review of an uncommon but treatable malignancy. Clinical and Translational Oncology, 2015, 17, 757-762.	2.4	7
68	Cancer of Unknown Primary origin in the genomic era: Elucidating the dark box of cancer. Cancer Treatment Reviews, 2015, 41, 598-604.	7.7	46
69	The role of human papilloma virus and p16 in occult primary of the head and neck: A comprehensive review of the literature. Oral Oncology, 2015, 51, 119-123.	1.5	22
70	A mini review on cancer of unknown primary site: A clinical puzzle for the oncologists. Journal of Advanced Research, 2015, 6, 375-382.	9.5	93
71	An unusual presentation of a patient with advanced prostate cancer, massive ascites and peritoneal metastasis: Case report and literature review. Journal of Advanced Research, 2015, 6, 517-521.	9.5	27
72	Development of a low grade lymphoma in the mastoid bone in a patient with atypical Coganâ€™s syndrome: A case report. Journal of Advanced Research, 2015, 6, 523-527.	9.5	3

#	ARTICLE	IF	CITATIONS
73	Cancer of unknown primary during pregnancy: an exceptionally rare coexistence. <i>Anticancer Research</i> , 2015, 35, 575-9.	1.1	4
74	A patient with neuroendocrine carcinoma of the urinary bladder and paraneoplastic degenerative parencephalitis: A case report and review of the literature. <i>Cancer Treatment Communications</i> , 2014, 2, 8-11.	0.4	2
75	Renal cell carcinoma in pregnancy: a rare coexistence. <i>Clinical and Translational Oncology</i> , 2014, 16, 122-127.	2.4	80
76	Major depressive disorder in breast cancer: A critical systematic review of pharmacological and psychotherapeutic clinical trials. <i>Cancer Treatment Reviews</i> , 2014, 40, 349-355.	7.7	40
77	Psychosocial predictors of health outcomes in colorectal cancer: A comprehensive review. <i>Cancer Treatment Reviews</i> , 2014, 40, 800-809.	7.7	45
78	Relapsing Episodes of Loss of Consciousness in a Patient With Hepatocellular Carcinoma. <i>World Journal of Oncology</i> , 2014, 5, 214-219.	1.5	4
79	Cancer diagnosis in a cohort of patients with Sjogren's syndrome and rheumatoid arthritis: a single-center experience and review of the literature. <i>Anticancer Research</i> , 2014, 34, 6669-76.	1.1	11
80	Psychiatric manifestations, personality traits and health-related quality of life in cancer of unknown primary site. <i>Psycho-Oncology</i> , 2013, 22, 2009-2015.	2.3	35
81	Prognostication in cancer of unknown primary (CUP): Development of a prognostic algorithm in 311 cases and review of the literature. <i>Cancer Treatment Reviews</i> , 2013, 39, 701-708.	7.7	47
82	Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 431-439.	3.3	23
83	Exploring the biology of cancer of unknown primary: breakthroughs and drawbacks. <i>European Journal of Clinical Investigation</i> , 2013, 43, 491-500.	3.4	50
84	Cancer of Unknown Primary Site: The Pathologist's Point of View. <i>The Journal of Oncopathology</i> , 2013, 1, 47-54.	0.1	1
85	Prognostic Significance of ESR1 Gene Amplification, mRNA/Protein Expression and Functional Profiles in High-Risk Early Breast Cancer: A Translational Study of the Hellenic Cooperative Oncology Group (HeCOG). <i>PLoS ONE</i> , 2013, 8, e70634.	2.5	15
86	Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a study of 100 CUP cases. <i>Annals of Oncology</i> , 2012, 23, 2725-2730.	1.2	16
87	Cancer of unknown primary site. <i>Lancet, The</i> , 2012, 379, 1428-1435.	13.7	468
88	Does psychological distress vary between younger and older adults in health and disease?. <i>Journal of Psychosomatic Research</i> , 2012, 72, 120-128.	2.6	22
89	Long-term survivors among patients with cancer of unknown primary. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 85-92.	4.4	19
90	Profiling clinical cancer research across the Atlantic: A review of research and its characteristics presented at ASCO and ESMO Congresses during the last decade. <i>Cancer Treatment Reviews</i> , 2012, 38, 560-565.	7.7	1

#	ARTICLE	IF	CITATIONS
91	Prognosis of pregnancy-associated breast cancer: A meta-analysis of 30 studies. <i>Cancer Treatment Reviews</i> , 2012, 38, 834-842.	7.7	199
92	Profiling immunohistochemical expression of NOTCH1, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 603-614.	3.3	15
93	Improved Outcome of High-Risk Early HER2 Positive Breast Cancer With High CXCL13-CXCR5 Messenger RNA Expression. <i>Clinical Breast Cancer</i> , 2012, 12, 183-193.	2.4	49
94	Cancer prevalence and mortality in centenarians: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 145-152.	4.4	69
95	Undergraduate training in oncology: An ESO continuing challenge for medical students. <i>Surgical Oncology</i> , 2012, 21, 15-21.	1.6	34
96	Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management. <i>Annals of Gastroenterology</i> , 2012, 25, 106-118.	0.6	119
97	Immunohistochemical study of the epithelial-mesenchymal transition phenotype in cancer of unknown primary: incidence, correlations and prognostic utility. <i>Anticancer Research</i> , 2012, 32, 1273-81.	1.1	25
98	Cancer of unknown primary patients with midline nodal distribution: Midway between poor and favourable prognosis?. <i>Cancer Treatment Reviews</i> , 2011, 37, 120-126.	7.7	25
99	Neuroendocrine carcinoma of unknown primary: A systematic review of the literature and a comparative study with other neuroendocrine tumors. <i>Cancer Treatment Reviews</i> , 2011, 37, 358-365.	7.7	58
100	Personality variables as predictors of early non-metastatic colorectal cancer patients' psychological distress and health-related quality of life: A one-year prospective study. <i>Journal of Psychosomatic Research</i> , 2011, 70, 411-421.	2.6	63
101	Cancer and pregnancy: what should we know about the management with systemic treatment of pregnant women with cancer?. <i>European Journal of Cancer</i> , 2011, 47, S348-S352.	2.8	17
102	Prognostic utility of β -tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 179-193.	2.5	36
103	Euro-Arab School of Oncology: an Educational Collaborative Activity of the European School of Oncology with the Arab World. <i>Journal of Cancer Education</i> , 2011, 26, 129-133.	1.3	2
104	Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study. <i>Anti-Cancer Drugs</i> , 2010, 21, 785-789.	1.4	4
105	Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 1-11.	2.5	93
106	Serous papillary peritoneal carcinoma: Unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 75, 27-42.	4.4	79
107	Probing the unknown in cancer of unknown primary: which way is the right way?. <i>Annals of Oncology</i> , 2010, 21, 1143-1144.	1.2	4
108	Lung cancer in the pregnant woman: To treat or not to treat, that is the question. <i>Lung Cancer</i> , 2010, 67, 251-256.	2.0	56

#	ARTICLE	IF	CITATIONS
109	High levels of topoisomerase III β protein expression in diffuse large B-cell lymphoma are associated with high proliferation, germinal center immunophenotype, and response to treatment. <i>Leukemia and Lymphoma</i> , 2010, 51, 1260-1268.	1.3	14
110	Treatment of the pregnant mother with cancer: A systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: Solid tumors. <i>Cancer Treatment Reviews</i> , 2010, 36, 101-109.	7.7	117
111	Treatment of the pregnant mother with cancer: A systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: Hematological tumors. <i>Cancer Treatment Reviews</i> , 2010, 36, 110-121.	7.7	141
112	Cancer of Unknown Primary: What Kind of Chemotherapy? What Kind of Disease?. <i>Oncology Research and Treatment</i> , 2009, 32, 159-160.	1.2	3
113	Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 6454-6461.	7.0	97
114	Successful publishing: How to get your paper accepted. <i>Surgical Oncology</i> , 2009, 18, 350-356.	1.6	28
115	Treatment for Patients With Unknown Primary Carcinoma and Unfavorable Prognostic Factors. <i>Seminars in Oncology</i> , 2009, 36, 65-74.	2.2	87
116	Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 131-143.	2.5	61
117	Donor-derived breast cancer in a bone marrow transplantation recipient. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 211-213.	2.5	17
118	Somatization is associated with physical health-related quality of life independent of anxiety and depression in cancer, glaucoma and rheumatological disorders. <i>Quality of Life Research</i> , 2009, 18, 1029-1042.	3.1	30
119	Screening practice and misplaced priorities. <i>Clinical and Translational Oncology</i> , 2009, 11, 228-236.	2.4	3
120	Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site: a favourable prognosis subset of patients with CUP. <i>Clinical and Translational Oncology</i> , 2009, 11, 340-348.	2.4	53
121	Presentation, Management and Outcome of 32 Patients with Pregnancy-Associated Breast Cancer: A Matched Controlled Study. <i>Breast Journal</i> , 2009, 15, 461-467.	1.0	79
122	Carcinoma of unknown primary (CUP). <i>Critical Reviews in Oncology/Hematology</i> , 2009, 69, 271-278.	4.4	210
123	Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: A systematic literature review. <i>Cancer Treatment Reviews</i> , 2009, 35, 221-227.	7.7	80
124	Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: Multiple-treatments meta-analysis. <i>Cancer Treatment Reviews</i> , 2009, 35, 570-573.	7.7	109
125	Evidence-based medicine: Development and implementation of guidelines in oncology. <i>European Journal of Cancer</i> , 2009, 45, 468-470.	2.8	8
126	Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 237-247.	4.4	37

#	ARTICLE	IF	CITATIONS
127	Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: Accumulating evidence of efficacy, synergy and safety. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 31-41.	4.4	32
128	Liver metastases from cancer of unknown primary (CUPL): A retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature. <i>Cancer Treatment Reviews</i> , 2008, 34, 693-700.	7.7	56
129	Gastrointestinal, Urologic and Lung Malignancies During Pregnancy. , 2008, 178, 137-164.		14
130	Personality Factors Associated With Psychological Distress in Testicular Cancer Survivors. <i>Journal of Personality Assessment</i> , 2008, 90, 348-355.	2.1	13
131	Metastatic Involvement of Placenta and Foetus in Pregnant Women with Cancer. , 2008, 178, 183-194.		51
132	Forty years experience of treating cancer of unknown primary. <i>Acta OncolÃ³gica</i> , 2007, 46, 592-601.	1.8	68
133	Cancer of Unknown Primary Site: Missing Primary or Missing Biology?. <i>Oncologist</i> , 2007, 12, 418-425.	3.7	127
134	Response: Re: Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2007, 99, 176-177.	6.3	1
135	Switching benchmarks in cancer of unknown primary: From autopsy to microarray. <i>European Journal of Cancer</i> , 2007, 43, 2026-2036.	2.8	229
136	Effects of different chemotherapy regimens on survival for advanced cervical cancer: Systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2007, 33, 24-38.	7.7	35
137	Editorial: Adolescent oncology. <i>Cancer Treatment Reviews</i> , 2007, 33, 595-596.	7.7	3
138	Late toxicity in survivors from adolescent cancers. <i>Cancer Treatment Reviews</i> , 2007, 33, 656-663.	7.7	15
139	Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. <i>Lancet Oncology</i> , The, 2007, 8, 898-911.	10.7	149
140	Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target?. <i>Clinical and Experimental Metastasis</i> , 2007, 24, 79-86.	3.3	26
141	Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival. <i>Breast Cancer Research and Treatment</i> , 2006, 100, 161-167.	2.5	14
142	Treatment of colorectal cancer in the elderly: A review of the literature. <i>Cancer Treatment Reviews</i> , 2006, 32, 1-8.	7.7	64
143	Cancer treatment reviews welcomes submission of the Cochrane Reviews. <i>Cancer Treatment Reviews</i> , 2006, 32, 243-244.	7.7	1
144	Perspectives for targeted therapies in cancer of unknown primary site. <i>Cancer Treatment Reviews</i> , 2006, 32, 637-644.	7.7	18

#	ARTICLE	IF	CITATIONS
145	Cancer and pregnancy: Poena magna, not anymore. <i>European Journal of Cancer</i> , 2006, 42, 126-140.	2.8	229
146	Feasibility study and pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction. <i>Anti-Cancer Drugs</i> , 2006, 17, 1219-1222.	1.4	6
147	Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. <i>Breast Cancer Research and Treatment</i> , 2006, 97, 237-244.	2.5	101
148	Elderly patients with squamous lung carcinoma: faring better or worse?. <i>Supportive Care in Cancer</i> , 2006, 14, 867-870.	2.2	1
149	«Juvenile» oncology - a missing subspecialty. The experience of a reference cancer centre. <i>Clinical and Translational Oncology</i> , 2006, 8, 444-449.	2.4	1
150	Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1285-1291.	6.3	242
151	Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1655-1663.	6.3	159
152	Old habits die hard: chest radiography for screening purposes in primary care. <i>American Journal of Managed Care</i> , 2006, 12, 650-6.	1.1	5
153	Cancer of unknown primary (CUP). <i>Critical Reviews in Oncology/Hematology</i> , 2005, 54, 243-250.	4.4	147
154	Prognostic Factors in Patients with Colorectal Cancer Receiving Adjuvant Chemotherapy or Chemoradiotherapy: A Pooled Analysis of Two Randomized Studies. <i>International Journal of Gastrointestinal Cancer</i> , 2005, 36, 029-038.	0.4	5
155	Paclitaxel, Cisplatin, Leucovorin, and Continuous Infusion Fluorouracil Followed by Concomitant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Hellenic Cooperative Oncology Group Phase II Study. <i>Medical Oncology</i> , 2005, 22, 269-280.	2.5	7
156	Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. <i>BMC Cancer</i> , 2005, 5, 25.	2.6	58
157	Matrix metalloproteinases in carcinoma of unknown primary. <i>Cancer</i> , 2005, 104, 2282-2287.	4.1	32
158	Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 358-360.	2.3	38
159	Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: Active, but how effective?. <i>Acta Oncologica</i> , 2005, 44, 155-160.	1.8	25
160	Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2005, 97, 188-194.	6.3	1,018
161	Oxaliplatin (Eloxatin®, [©]) Plus Irinotecan Combination Chemotherapy Found Effective in Refractory Metastatic Insular Thyroid Carcinoma. <i>Thyroid</i> , 2005, 15, 614-617.	4.5	3
162	Brain metastasis of unknown primary: A diagnostic and therapeutic dilemma. <i>Cancer Treatment Reviews</i> , 2005, 31, 247-255.	7.7	55

#	ARTICLE	IF	CITATIONS
163	The pregnant mother with breast cancer: Diagnostic and therapeutic management. <i>Cancer Treatment Reviews</i> , 2005, 31, 439-447.	7.7	82
164	Inflammatory prostate cancer: An underestimated paraneoplastic clinical manifestation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005, 23, 318-322.	1.6	14
165	Management of leptomeningeal malignancy. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1115-1125.	1.8	53
166	Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study. <i>Anticancer Research</i> , 2005, 25, 3103-8.	1.1	18
167	Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 53, 452-457.	2.3	46
168	Metastatic breast carcinoma confined to bone. <i>Cancer</i> , 2004, 101, 1524-1528.	4.1	61
169	Intensified Bimonthly Cisplatin With Bolus 5-Fluorouracil, Continuous 5-Fluorouracil and High-Dose Leucovorin (LV5FU2) in Patients With Advanced Gastrointestinal Carcinomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 465-471.	1.3	2
170	Biweekly Administration of Low-Dose Docetaxel in Hormone-Resistant Prostate Cancer: Pilot Study of an Effective Subtoxic Therapy. <i>Clinical Prostate Cancer</i> , 2003, 2, 46-49.	2.1	13
171	Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study. <i>Anti-Cancer Drugs</i> , 2002, 13, 481-489.	1.4	17
172	Dose-Dense Sequential Chemotherapy With Epirubicin and Paclitaxel Versus the Combination, as First-Line Chemotherapy, in Advanced Breast Cancer: A Randomized Study Conducted by the Hellenic Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2001, 19, 2232-2239.	1.6	22
173	G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting. <i>Cancer</i> , 2001, 91, 909-917.	4.1	18
174	Dose-Dense Sequential Chemotherapy with Epirubicin and Paclitaxel in Advanced Breast Cancer. <i>Cancer Investigation</i> , 2001, 19, 137-144.	1.3	4
175	Noncardiogenic Pulmonary Edema: An Unusual and Serious Complication of Anticancer Therapy. <i>Oncologist</i> , 2001, 6, 153-161.	3.7	86
176	Carboplatin Plus Paclitaxel in Unknown Primary Carcinoma: A Phase II Hellenic Cooperative Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 3101-3107.	1.6	182
177	Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG). <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 167-171.	2.3	37
178	Phase I Trial of 6-Hour Infusion of Glufosfamide, a New Alkylating Agent With Potentially Enhanced Selectivity for Tumors That Overexpress Transmembrane Glucose Transporters: A Study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group. <i>Journal of Clinical Oncology</i> , 2000, 18, 3535-3544.	1.6	54
179	Chemotherapy-Induced Noncardiogenic Pulmonary Edema Related to Gemcitabine plus Docetaxel Combination with Granulocyte Colony-Stimulating Factor Support. <i>Respiration</i> , 2000, 67, 680-683.	2.6	28
180	Docetaxel and Gemcitabine in Anthracycline-Resistant Advanced Breast Cancer: A Hellenic Cooperative Oncology Group Phase II Study. <i>Cancer Investigation</i> , 2000, 18, 503-509.	1.3	57

#	ARTICLE	IF	CITATIONS
181	High-dose epirubicin and r-met-hu G-CSF (Filgrastim) in the treatment of patients with advanced breast cancer: A hellenic cooperative oncology group study. Medical and Pediatric Oncology, 1995, 24, 23-28.	1.0	8
182	Evaluation of six tumor markers in patients with carcinoma of unknown primary. Medical and Pediatric Oncology, 1994, 22, 162-167.	1.0	53
183	Is androgen substitution necessary in hypogonadal patients when they are treated with chemotherapy for malignant diseases?. Medical and Pediatric Oncology, 1989, 17, 222-226.	1.0	2